BrainChild Bio Raises $116M Series A to Fund Phase 2 Pivotal Trial of BCB-276 for DIPG
BrainChild Bio raised $116 million in a Series A to fund the ILLUMINATE Phase 2 pivotal trial of BCB-276 for diffuse intrinsic pontine glioma (DIPG) and to advance BCB-214 and other CAR T programs for pediatric and adult brain tumors.
No comments yet.